geldanamycin

Geldanamycin, an HSP90 inhibitor (Kd: 1.2 μM), specifically disrupts glucocorticoid receptor (GR)/HSP association.

7-Descarbamoyl-17-amino geldanamycin is a derivative of Geldanamycin. It exhibits very low activity in depleting the p185erbB-2 protein in vitro in human breast cancer cells.

Aminohexylgeldanamycin (AHGDM), a derivative of Geldanamycin, is a highly effective inhibitor of HSP90. It exhibits considerable antiangiogenic and antitumor properties[1].

Aminohexylgeldanamycin (AHGDM) hydrochloride is a Geldanamycin derivative and a powerful inhibitor of HSP90. It exhibits significant antiangiogenic and antitumor properties.

17-O-Demethylgeldanamycin is a secondary metabolite that can be isolated from Streptomyces. It exhibits cytotoxic effects against various tumor cells, demonstrating antitumor activity.

IPI-493 (17-amino17demethoxy) is a novel HSP90 inhibitor with antitumor activity.

2-Methoxyhydroquinone inhibits MAO-A and MAO-B and reduces TNF-α-induced CCL2 production, often serving as a precursor for synthesising the Hsp90 inhibitor Geldanamycin.

17-DMAP-GA, a Geldanamycin analogue, acts as an HSP90 inhibitor, leading to cell cycle abnormalities.

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].

3-Amino-5-hydroxybenzoic acid-13C is the 13C-labeled version of 3-Amino-5-hydroxybenzoic acid. This compound, also known as AHBA, serves as a biosynthetic precursor to the mC7N unit of ansamycin class antibiotics, including ansamitocin and geldanamycin, as well as the antitumor antibiotic mitomycin C. It is likely derived from an early intermediate in the shikimic acid pathway originating from glucose.